(UG) United-Guardian - Ratings and Ratios

United-Guardian, Inc. (NASDAQ:UG) is a specialty chemical and pharmaceutical company that develops, manufactures, and markets a diverse range of products for the personal care, pharmaceutical, medical, and industrial sectors. The companys product portfolio includes advanced cosmetic ingredients, medical lubricants, prescription pharmaceuticals, and proprietary industrial solutions. Its cosmetic ingredients are designed to enhance sensory, moisturizing, and textural properties in personal care products, with offerings such as LUBRAJEL, a water-based gel formulation, and LUBRAJEL NATURAL, a plant-based moisturizing agent. The company also produces medical lubricants like LUBRAJEL RR and RC, which are used for urinary catheters and other medical devices. Its pharmaceutical division includes RENACIDIN, a prescription drug for preventing and dissolving calcifications in urinary catheters, and CLORPACTIN WCS-90, an antimicrobial agent used in urology. Industrial products like DESELEX, a sequestering agent for detergents, and THOROCLENS, a chlorine-based cleanser, round out its offerings. United-Guardian has operated since 1942 and is headquartered in Hauppauge, New York, with a strong focus on research and development to maintain its competitive edge in niche markets.

The company’s financial profile reflects its position as a small-cap entity with a market capitalization of $44.61M. Its trailing P/E ratio of 12.78 indicates moderate valuation relative to earnings, while its price-to-book ratio of 4.36 suggests that investors place a premium on its assets and future prospects. The price-to-sales ratio of 3.92 highlights the company’s revenue generation efficiency. United-Guardian’s return on equity (RoE) of 30.62% underscores its profitability relative to shareholder equity. However, its forward P/E is currently unavailable, which may reflect limited visibility into future earnings estimates.

Technically, the stock has shown recent weakness, trading below its 20-day and 50-day moving averages of 10.43 and 10.23, respectively. The 200-day moving average of 10.88 suggests that the stock has been in a downtrend over the longer term. Average trading volume over the past 20 days is 8,104 shares, indicating low liquidity, which could amplify price volatility. The Average True Range (ATR) of 0.37 reflects moderate price movement expectations.

3-Month Forecast: Based on the intersection of technical and fundamental data, United-Guardian’s stock is likely to face resistance at its 20-day and 50-day moving averages (10.43 and 10.23, respectively). The recent price of 9.70 suggests a potential retest of these levels, but the low average volume may limit upward momentum. Fundamental strength, particularly its high RoE and established product portfolio, could provide support. However, the absence of a forward P/E and limited trading liquidity may constrain near-term upside. Expect price action to remain range-bound between 9.00 and 11.00, with potential for a breakout above 11.00 if the company reports positive earnings or operational developments.